Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

2.1K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.1K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

1.2K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.2K
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

1.1K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.1K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

4.9K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
4.9K
Urinary Tract Calculi V: Nursing Management01:28

Urinary Tract Calculi V: Nursing Management

333
AssessmentSubjective Data: Obtain a detailed health history, including any recent or chronic urinary tract infections, periods of immobilization, previous episodes of renal calculi, and medical conditions such as gout, benign prostatic hyperplasia, or hyperparathyroidism. Review the medication history for drugs that may influence stone formation, including allopurinol, analgesics, loop diuretics, or thiazide diuretics. Document the use of long-term indwelling catheters and any past surgical...
333
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

219
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
219

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Duration of clinically meaningful improvement in pain as a patient-centered endpoint in acute pain trials.

Pain·2026
Same author

The Current Scope of Pain Medicine Fellowships: A Cross-Sectional Survey Study of Trainees, Directors, and Employers on Shaping Future Leaders.

Journal of pain research·2026
Same author

Real World Treatment Patterns Among Patients with Painful Diabetic Peripheral Neuropathy in the United States.

Pain medicine (Malden, Mass.)·2026
Same author

A National Fetal Alcohol Spectrum Disorders Learning Collaborative for Pediatric Care Teams.

Journal of pediatrics. Clinical practice·2026
Same author

From purity to proportionality: managing nonfinancial conflicts of interest in pain medicine.

Pain medicine (Malden, Mass.)·2026
Same author

Debunking myths in facial pain diagnosis for the pain practitioner.

Regional anesthesia and pain medicine·2026

Related Experiment Video

Updated: Feb 17, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

10.4K

Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations.

Charles E Argoff1, Daniel P Alford2, Jeffrey Fudin3

  • 1Department of Neurology, Albany Medical Center, Albany, New York.

Pain Medicine (Malden, Mass.)
|December 6, 2017
PubMed
Summary

Urine drug monitoring (UDM) is recommended for patients on chronic pain opioid therapy. This involves regular testing, with frequency based on individual risk, to aid comprehensive risk management.

Keywords:
Chronic PainOpioidsPain ManagementScreening ToolsSubstance Use DisordersUrine Drug Monitoring

More Related Videos

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

13.2K
Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
07:23

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

34.2K

Related Experiment Videos

Last Updated: Feb 17, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

10.4K
Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

13.2K
Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
07:23

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

34.2K

Area of Science:

  • Pain Management
  • Clinical Toxicology
  • Pharmacology

Background:

  • Opioid therapy for chronic pain necessitates careful patient monitoring.
  • Urine drug monitoring (UDM) is a key tool in assessing adherence and detecting aberrant drug use.
  • Existing guidelines for UDM in chronic pain patients require consensus and refinement.

Purpose of the Study:

  • To establish consensus-based recommendations for urine drug monitoring (UDM) in patients with chronic pain receiving opioid therapy.
  • To provide clear guidance on the appropriate use and frequency of UDM.

Main Methods:

  • An interdisciplinary panel of experts in pain, substance use disorders, and primary care convened virtually.
  • Literature review and analysis of existing guidelines were conducted.
  • Clinical experience was shared to reach consensus on UDM recommendations.

Main Results:

  • Definitive testing (chromatography-based) is preferred for UDM accuracy, though presumptive testing may be initially required.
  • UDM substance selection should be individualized, considering patient history and illicit drug availability.
  • Opioid risk stratification should incorporate patient history, PDMP data, risk assessment tools, and prior UDM.
  • Recommended UDM frequency: baseline for most, annually for low risk, biannually for moderate risk, and quarterly for high risk, with additional testing as clinically indicated.

Conclusions:

  • Despite limited evidence on UDM's efficacy in preventing opioid use disorder, overdose, or diversion, it is recommended.
  • UDM is a crucial component of comprehensive risk monitoring for patients on chronic opioid therapy.